Free Trial
→ Trump’s Exec Order #14154 could be a “Millionaire-Maker” (From Paradigm Press) (Ad)
NASDAQ:TNFA

TNF Pharmaceuticals 8/19/2024 Earnings Report

TNF Pharmaceuticals logo
$0.14 -0.02 (-10.57%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.14 +0.00 (+0.73%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

TNF Pharmaceuticals EPS Results

Actual EPS
-$1.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TNF Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TNF Pharmaceuticals Announcement Details

Quarter
Date
8/19/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

TNF Pharmaceuticals' next earnings date is estimated for Monday, August 18, 2025, based on past reporting schedules.

Conference Call Resources

TNF Pharmaceuticals Earnings Headlines

TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules
May 9, 2025 | tipranks.com
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
May 8, 2025 | businesswire.com
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
June 16, 2025 | Brownstone Research (Ad)
TNF Pharmaceuticals uses AI to refine patient selection for trials
April 24, 2025 | uk.investing.com
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
April 22, 2025 | finance.yahoo.com
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish
April 22, 2025 | msn.com
See More TNF Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TNF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TNF Pharmaceuticals and other key companies, straight to your email.

About TNF Pharmaceuticals

TNF Pharmaceuticals (NASDAQ:TNFA) operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

View TNF Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles